IP Library Granted Patent US 9,913,801
Granted Patent B2
US 9,913,801 · App. 14/768,007 · Granted Mar 13, 2018

Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione

Inventor: Frederick Timothy Guilford (Palo Alto, CA)
Assignee: YOUR ENERGY SYSTEMS, LLC
A61K9/127A61K9/0095A61K9/4858A61K31/407A61K31/43A61K31/59A61K38/063A61K45/06C12Q1/06C12Q1/18G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,913,801
App. No.
14/768,007
Granted
Mar 13, 2018
Kind
B2
Abstract

The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.

Claims (8)

1. A method of measuring the effectiveness of treatment of a patient using liposomal reduced glutathione in combination with an antibiotic against an antibiotic-resistant bacteria normally treated by said antibiotic, comprising the following steps:

initially measuring TGF-β in the blood plasma of a patient;

if TGF-beta is above a normal level administering, to a patient having disease symptoms arising from anti-biotic resistant strains of bacteria of Klebsiella pneumoniae , intravenously and thereafter if patient compliance can be assured, orally, a dose of a reduced glutathione stabilized and encapsulated in a liposomal pharmaceutical carrier capable of being ingested orally, and capable of delivering glutathione (reduced) in a physiologically active state to improve symptoms in disease states by transfer of the glutathione into animal cells, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM;

simultaneously administering the course of antibiotic through the recommended course of administration of said antibiotic;

measuring the reduction of elevated TGF-β in blood plasma;

measuring whether the level of said bacteria has fallen; and thereafter continuing to administer said glutathione and re-measuring said level of said bacterial until normal bodily health is achieved.

2. The method according to claim 1 , further comprising the following step:

administering Vitamin D.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded May 31, 2017
From: GUILFORD, F. (FREDERICK) TIMOTHY
To: YOUR ENERGY SYSTEMS, LLC
Reel/Frame 042547/0496 →
Continuity (3)
Provisional Application 61767464 · Feb 21, 2013
Provisional Application 61765379 · Feb 15, 2013
Related Publication 20150374626A1 · Dec 31, 2015